Methods: This study enrolled 21 female patients who participated in two previous clinical studies designed to assess the efficacy and safety of peroneal eTNM^®. The patients were left without subsequent OAB treatment and were invited to attend regular follow-up visits every 3 months. The patient’s request for additional treatment was considered an indicator of the withdrawal of the treatment effect of the initial course of peroneal eTNM^®. The primary objective was the proportion of patients with persisting treatment effect at follow-up visit 12 months after initial course of peroneal eTNM^®. Descriptive statistics are presented using median, correlation analyses were computed using a nonparametric Spearman correlation.

Results: The proportion of patients with persistent therapeutic effect of the initial course of peroneal eTNM^® was 76%, 76%, 62% and 48% at 3, 6, 9 and 12 months, respectively. There was a significant correlation between patient reported outcomes and the number of severe urgency episodes with or without urgency incontinence as reported by patients at each follow-up visit (p = 0.0017).

Conclusion: The treatment effect achieved during the initial phase of peroneal eTNM^® persists for at least 12 months in 48% of patients. It is likely that the duration of effects is dependent on the length of the initial therapy.